Human Senescence Atlas Turns Aging Into a Mapping Problem
NIH's SenNet atlas does not prove an anti-aging therapy. It gives longevity science a harder measurement layer.
Read the briefing →Frontier 03 / Longevity
Longevity science sits between evidence and ambition.
Vastkind follows aging biology, interventions, biomarkers, and the hard difference between mechanism, animal data, and human proof.
Biomarkers
Interventions
Human proof
Current signal
Latest ↓
Start here
Three questions for reading Longevity.
What is changing?
Aging is increasingly treated as a biological and measurement problem, not just fate.
What should readers watch?
Human evidence, biomarkers, trial design, intervention claims, and regulatory acceptance.
What should readers doubt?
Any claim that jumps from mechanism to guaranteed human benefit.
Read now
Latest Longevity signals.
Newest longevity stories, with evidence separated from optimism.
David Sinclair's XPRIZE Rejuvenation Plan Has a Proof Problem
The real story is not another anti-aging pill claim. It is whether whole-body rejuvenation can survive XPRIZE's measurement machine.
ER-100 First Human Dosed: The Rejuvenation Test Has Left the Lab
The first human dosing of ER-100 does not prove age reversal. It starts the evidence clock for one of longevity's boldest ideas.
Semaglutide Failed in Alzheimer's. The Bigger Lesson Is About Evidence.
Two major Alzheimer's trials showed semaglutide did not slow clinical decline. The result is a hard lesson in what evidence can and cannot prove.
What Is Longevity Science? How Aging Biology Works, What Human Evidence Shows, and Where Claims Break
Longevity science is real. The hard part is knowing which claims have moved from mechanism to human proof.
The Longevity Industry Has a Measurement Problem
Longevity will not become serious medicine until it proves what its numbers actually mean.
Rapamycin Still Needs Human Proof
Rapamycin has real longevity science behind it. That does not make it a proven anti-aging drug for healthy humans.
Field note
Read the board before it turns into noise.
A compact operating note for Longevity: what changed, what to watch, what to doubt, and where the constraint sits.
Aging becomes an intervention target
The field is moving from vague anti-aging language toward mechanisms, trials, and measurable healthspan claims.
Validated biomarkers
Markers that predict meaningful outcomes, not just marketing narratives.
A biomarker change equals longer life.
Mouse results predict human benefit.
Human proof
Mechanisms and mouse results do not automatically become meaningful human outcomes.
Corridors
Routes around Longevity.
Use these routes when a story crosses into neighboring fields, forces, or reading formats.
Latest corridor story
Human Senescence Atlas Turns Aging Into a Mapping Problem
Latest corridor story
David Sinclair's XPRIZE Rejuvenation Plan Has a Proof Problem
Archive
All Longevity stories, compact.
Use the archive for retrieval; the map above carries the orientation.
Partial Epigenetic Reprogramming Human Trial: Longevity’s Reality Check
ER-100 is a narrow eye-disease trial, but it may be the first real test of whether cellular rejuvenation can survive clinical evidence.
AI + Quantum Longevity Forecast: The Kurzweil Narrative vs the Trial Timeline
Exponential tools are colliding with non-exponential biology.
Longevity Will Not Break the Planet by Itself. Frailty, Emissions, and Inequality Might.
Longevity does not automatically create planetary collapse. The real burden depends on whether extra years are healthy or dependent, low-carbon or resource-heavy, shared or stratified.
Biological Age Testing: What Epigenetic Clocks Can Tell You—and What They Can’t
Epigenetic clocks can be useful research tools and decent trend signals. They become dangerous when people treat them like destiny.
NMN vs NR in 2026: What Human Trials Actually Show
NMN and NR can move NAD-related biomarkers. That does not mean they have already proved meaningful anti-aging outcomes in humans.
Senolytics in Humans: Why the First Real Clinical Reality Check Matters More Than the Hype
UBX1325 is one of the clearest tests yet of whether senolytics can move from longevity mythology into real medicine.
Partial Reprogramming OSK vs OSKM: Why “Partial” Is the Whole Trick
The future of reprogramming depends less on ambition than on control.
David Sinclair’s Information Theory of Aging: Powerful Idea, Uneven Proof
Sinclair changed how longevity talks about aging. The hard question is how much of the theory will survive clinical reality.
The First Human Rejuvenation Trial: What ER-100 Really Changes
ER-100 matters because rejuvenation language is finally being forced to answer to medicine.
Longevity 2026: Why the Field Is Finally Facing Clinical Reality
Longevity is growing up. In 2026, the field is finally being judged by trials, endpoints, and clinical reality.
Ca-AKG Longevity Review: Real Benefits, Safe Doses, Bold Future
Ca-AKG is promising because it is plausible, not because the human case is already finished.
Glycine Review: What It Actually Helps With—and Where the Hype Runs Ahead of the Evidence
Glycine is one of the more credible low-cost sleep supplements, but its strongest case is narrower than the hype.
Mitopure Urolithin A Powder Review: Real Results or Hype?
One of the few longevity supplements with real human data still has to clear the price and expectation test.
Withings Body Scan Review: Is This Smart Scale Actually Worth $399?
The Withings Body Scan is ambitious, expensive, and unusually useful—if you know what you are buying.
Longevity Research: Why “Optional Death” Is a Powerful Idea—and a Dangerous Timeline Fantasy
Longevity research is becoming more credible, but the fantasy of optional death still moves much faster than the science.
Klotho Gene Therapy Is a Stress Test for Longevity, Not a One-Shot Anti-Aging Revolution
Klotho is not interesting because aging has been solved with one shot. It is interesting because it forces longevity to face the hard realities of gene-therapy translation.
Longevity 2030 Will Be Defined by Partial Wins, Not an Anti-Aging Revolution
The real longevity story by 2030 is not a miracle leap to 120. It is a harder transition where diagnostics, selective interventions, and unequal access move faster than grand promises.